ICLUSIG (ponatinib) patient profiles*

Identifying patients with CP-CML who may be appropriate for ICLUSIG

ICLUSIG may help patients with distinct clinical features and TKI resistance

Maddy with CP CML.

Resistant CML

“My diagnosis at 33 years old upended my life. Now I’m trying to survive this chronic disease, with minimal disruption to my daily routine.”

Maddy | 35

Recently engaged entrepreneur

Diagnosis:

CP-CML

Mutations in BCR::ABL:

None

Comorbidities:

None

BCR::ABL1:

16%

Prior Course of Treatment:

dasatinib (18 months), bosutinib (6 months)

Cynthia with CP CML.

Resistant CML

“As someone with a science background, I’m very involved in my CML treatment decisions. I always check each drug’s clinical track record to ensure I’m receiving an effective treatment that’s backed up by long-term data.”

Cynthia | 72

Retired mental health counselor with six grandkids

Diagnosis:

CP-CML

Mutations in BCR::ABL:

None

Comorbidities:

Diabetes (Controlled)

BCR::ABL1:

19%

Prior Course of Treatment:

nilotinib (33 months), dasatinib (15 months)

Alan with CP CML with the T315i mutation.

Mutation-positive CML

"According to my doctor, I just tested positive for a mutation in CML. I'm nervous to find out what this means for my treatment options."

Alan | 49

Chef and avid golfer

Diagnosis:

CP-CML

Mutations in BCR::ABL:

T315I

Comorbidities:

Hypertension (Controlled)

BCR::ABL1:

21%

Prior Course of Treatment:

imatinib (51 months)

*Hypothetical patient profiles

ICLUSIG demonstrated efficacy in CML

ICLUSIG shows efficacy in heavily pretreated, TK-resistant patients

BCR::ABL1IS=BCR::ABL1 international scale; CP=chronic phase; CP-CML=chronic phase chronic myeloid leukemia; CML=chronic myeloid leukemia; CV=cardiovascular; TKI=tyrosine kinase inhibitor.